Department of Orthopedics, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Department of Orthopedics, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
J Nanobiotechnology. 2022 Mar 19;20(1):150. doi: 10.1186/s12951-022-01367-z.
Osteoarthritis (OA) is a highly prevalent human degenerative joint disorder that has long plagued patients. Glucocorticoid injection into the intra-articular (IA) cavity provides potential short-term analgesia and anti-inflammatory effects, but long-term IA injections cause loss of cartilage. Synovial mesenchymal stem cells (MSCs) reportedly promote cartilage proliferation and increase cartilage content.
CD90 MCS-derived micro-vesicle (CD90@MV)-coated nanoparticle (CD90@NP) was developed. CD90 MCSs were extracted from human synovial tissue. Cytochalasin B (CB) relaxed the interaction between the cytoskeleton and the cell membranes of the CD90 MCSs, stimulating CD90@MV secretion. Poly (lactic-co-glycolic acid) (PLGA) nanoparticle was coated with CD90@MV, and a model glucocorticoid, triamcinolone acetonide (TA), was encapsulated in the CD90@NP (T-CD90@NP). The chondroprotective effect of T-CD90@NP was validated in rabbit and rat OA models.
The CD90@MV membrane proteins were similar to that of CD90 MCSs, indicating that CD90@MV bio-activity was similar to the cartilage proliferation-inducing CD90 MCSs. CD90@NP binding to injured primary cartilage cells was significantly stronger than to erythrocyte membrane-coated nanoparticles (RNP). In the rabbit OA model, the long-term IA treatment with T-CD90@NP showed significantly enhanced repair of damaged cartilage compared to TA and CD90 MCS treatments. In the rat OA model, the short-term IA treatment with T-CD90@NP showed effective anti-inflammatory ability similar to that of TA treatment. Moreover, the long-term IA treatment with T-CD90@NP induced cartilage to restart the cell cycle and reduced cartilage apoptosis. T-CD90@NP promoted the regeneration of chondrocytes, reduced apoptosis via the FOXO pathway, and influenced type 2 macrophage polarization to regulate inflammation through IL-10.
This study confirmed that T-CD90@NP promoted chondrocyte proliferation and anti-inflammation, improving the effects of a clinical glucocorticoid treatment plan.
骨关节炎(OA)是一种高度流行的人类退行性关节疾病,长期以来一直困扰着患者。关节内(IA)腔注射糖皮质激素可提供潜在的短期镇痛和抗炎作用,但长期 IA 注射会导致软骨丢失。滑膜间充质干细胞(MSCs)据报道可促进软骨增殖并增加软骨含量。
开发了 CD90 MSC 衍生的微泡(CD90@MV)包被的纳米颗粒(CD90@NP)。从人滑膜组织中提取 CD90 MSC。细胞松弛素 B(CB)放松了 CD90 MSC 细胞骨架与细胞膜之间的相互作用,刺激 CD90@MV 的分泌。聚(乳酸-共-羟基乙酸)(PLGA)纳米颗粒包被 CD90@MV,并将模型糖皮质激素,曲安奈德(TA)包封在 CD90@NP 中(T-CD90@NP)。在兔和大鼠 OA 模型中验证了 T-CD90@NP 的软骨保护作用。
CD90@MV 膜蛋白与 CD90 MSC 相似,表明 CD90@MV 生物活性与诱导软骨增殖的 CD90 MSC 相似。与红细胞膜包被的纳米颗粒(RNP)相比,CD90@NP 与受损的原代软骨细胞的结合明显更强。在兔 OA 模型中,与 TA 和 CD90 MSC 治疗相比,T-CD90@NP 的长期 IA 治疗明显增强了对受损软骨的修复。在大鼠 OA 模型中,T-CD90@NP 的短期 IA 治疗表现出与 TA 治疗相似的有效抗炎能力。此外,T-CD90@NP 的长期 IA 治疗诱导软骨重新启动细胞周期并减少软骨细胞凋亡。T-CD90@NP 通过 FOXO 通路促进软骨细胞增殖,减少凋亡,并通过 IL-10 影响 2 型巨噬细胞极化以调节炎症。
本研究证实 T-CD90@NP 可促进软骨细胞增殖和抗炎,改善临床糖皮质激素治疗方案的效果。